Navigation Links
Schering-Plough Announces Presentation of Phase II Trial Results,for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual,Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

The Phase II trial, with an abstract titled Results of a Multinational, Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, will be presented by the TRA-PCI investigators.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.sch
'"/>




Page: 1 2

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
(Date:11/25/2009)...25/PRNewswire-FirstCall/--HeskaCorporation(HSKA);(...specialtyproductstotheveterinaryindustry,announced...hesupplyofbloodgasproductsandaffiliatedconsumables...wscom.com/cgi-bin/prnh/20000622/HESKALOGO ) ,, ...efieldofadvancedpoint-of-carediagnostics,"commente...
(Date:11/25/2009)...25/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq: ...dtodiscovering,developingandcommercializingnoveldr...forthefiscalyearendedSeptember30,2009.AtSeptember3...entsandshortterminvestments. ,, PipelineUpdate...rial ,, InlateNovember2009,anindependentDataM...
(Date:11/25/2009)...tzerland,Nov.25/PRNewswire/-- FromNovember16-18,Ph...tions,presentedthesecondeditionoftheHearingCarefor...erpopulation.Theconferencebroughttogetherleadingex...han250clinicianswhoworkeverydaywitholderpeoplewith...scussthelatestresearchandtrendsinhearingcareforold...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3QHR and Valley Health Amicably Part Ways 48030 1QHR and Valley Health Amicably Part Ways 48030 2New Provisional Restorations In Dentistry DVD by Paul R Chalifoux DDS 48026 1New Provisional Restorations In Dentistry DVD by Paul R Chalifoux DDS 48026 2Angelica Corporation Raises Bar Again for Increased Patient Safety 48022 1Angelica Corporation Raises Bar Again for Increased Patient Safety 48022 2
...Panelists to Discuss Trends, Trials, and Innovatio... Conferences, CLEVELAND, Sept. 25 Cleveland Clin... on medical innovation and emerging trends,in card...riving the development of new therapies, treat... The 5th annual Cleveland Clinic Medical Inno...
...rena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today a...se 2 clinical trial of APD125 in patients with chr...candidate discovered by Arena that is being,evalua...aining sleep after,initial sleep onset. When compa...ienced statistically significant improvements in m...
Other Medicine Technology:Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation 2Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 5Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 6Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 7
(Date:11/25/2009)...swire/--TheAmericanAssociationforHomecareendorsest...hisdesignedtosubstantiallyimprovetoolsandresources...ucedbySen.GeorgeLeMieux(R-Fla.). ,, TheLeMieuxb...forHomecareoutlinedinits13-pointanti-fraudactionpl....Thoseprovisionsincludecallingforreal-timeauditsan...
(Date:11/25/2009)...d into the body on a carefully engineered, fingern...minate tumors in mammals, scientists report this w... . , The new approach, pioneered by bioengineers...stic disks impregnated with tumor-specific antigen...mmalian immune system to attack tumors. The new pa...
(Date:11/25/2009)...r in children with autism and related conditions c...medication combined with a structured training pro...earchers and their colleagues. , Published in t...ican Academy of Child and Adolescent Psychiatry , ...of Mental Health (NIMH) Research Units on Pediatri...
(Date:11/25/2009)...ed parts of speech colored perception of sounds ,... People can "hear" not only with their ears, but a...act, sensations on the skin designed to mimic cert...r sounds better, the Canadian scientists found. ,...ld use tactile information in this way," said Brya...
(Date:11/25/2009)...to include cost-effective, sustainable distance tr...essionals in developing world. , ...- Elluminate, Inc. , the leader in web, audio, v... 21st century teaching, learning, and collaboratio...ive was awarded iNACOL,s first-ever Outstanding a...
Breaking Medicine News(10 mins):Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5
...pment of cancer. Cells without this protein are us...ity would either kill a cell or keep it from growi...h a way that they are able to multiply creating tu...// E2F3 is part of a family of proteins called tra...
...se electrocardiograph tests should be the first-li... patients with chest pain. Even though negative fi...ings could not distinguish levels of risk. The res...inical or exercise electrocardiography.// They com...
...p to 10, authorities are not confident about the g...wn a far higher recovery rate than the rest of the... medical care provided to SARS patients. Even what...tist at the National Institute of Communicable Dis...
...everal countries are forecast to shrink in the sec...s, from Filipina maids to Indonesian laborers and ...ommerce in the region, sending home in excess of $...irectly improving standards of living// and boosti...
...dian clinics where staffs worried about catching t...vernment hospital. Private medical centre closed t...ARS infected patients. The patients include a brid...e quarantined later to check if they developed sym...
...ay probably be small if the trip isn't to Asia. Pu...ently known about the virus. However people can be... strong filters against viruses. There have even b... filters to screen out spores, bacteria and viruse...
Other Medicine News:
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: